Bioidentical progesterone cream for menopause-related vasomotor symptoms: Is it effective?

Annals of Pharmacotherapy

Volumn 47, Issue 1, 2013, Pages 112-116

  Whelan, Anne Marie ^a   Jurgens, Tannis M ^b   Trinacty, Melanie ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOIDENTICAL PROGESTERONE; ESTROGEN; FOLLITROPIN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PROFEME; PROGESTELLE; PROGESTERONE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ARTICLE; BLOATING; CHEMICAL STRUCTURE; CREAM; DRUG ABSORPTION; DRUG EFFICACY; FOLLITROPIN BLOOD LEVEL; HEADACHE; HORMONAL THERAPY; HOT FLUSH; HUMAN; MENOPAUSE RELATED DISORDER; METABOLIC DISORDER; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMATIC REVIEW; VAGINA BLEEDING; VASOMOTOR DISORDER; WEIGHT GAIN;

FEMALE; HORMONE REPLACEMENT THERAPY; HOT FLASHES; HUMANS; MENOPAUSE; PROGESTERONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN CREAM; VASOMOTOR SYSTEM;

EID: 84872923815     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R362     Document Type: Article

References (32)

1. Reid RL, Blake J, Khan A, Senikas V, Fortier M. Menopause and osteo- porosis update. JOGC 2009;31:S1-S49.
2. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of es- trogen plus progestin in healthy postmenopausal women: principal re- sults from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
3. Food and Drug Administration. Bio-identicals: sorting myth from fact. www.fda.gov/downloads/ForConsumers/ConsumerUpdates/ucm049312. pdf (accessed 2012 Aug 15).
4. Bhavnani B, Stanczyk F. Misconception and concerns about bioidentical hormones used for custom-compounded hormone therapy. J Clin En- docrinol Metab 2012;97:756-9.
5. Whelan AM, Jurgens TM, Trinacty M. Defining bioidentical hormones for menopause-related symptoms. Pharmacy Practice 2011;9:16-22.
6. Holtorf K. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than com- monly used synthetic versions in hormone replacement therapy? Post- grad Med 2009;121:73-85. doi: 10.3810/pgm.2009.01.1949.
7. Somers S. Ageless: the naked truth about bioidentical hormones. 1st ed. New York: Crown Publishing Group, 2006.
8. McKee J, Warber SL. Integrative therapies for menopause. South Med J 2005;98:319-326.
9. Lakey S, Reed S, LaCroix A, Grothaus L, Newton K. Self-reported changes in providers' hormone therapy prescribing and counseling practices after the Women's Health Initiative. J Womens Health 2010;19:2175-2181.
10. Kupferer E, Dormirie S, Becker H. Complementary and alternative medicine use for vasomotor symptoms among women who have discon- tinued hormone therapy. J Obstet Gynecol Neonatal Nurs 2009;38:50-59.
11. MacLennan A, Gill T, Broadbent J, Taylor A. Continuing decline in hor- mone therapy use: population trends over 17 years. Climacteric 2009; 12:122-130.
12. Iftikhar S, Shuster L, Johnson R, Jenkins S, Wahner-Roedler D. Use of bioidentical compounded hormones for menopausal concerns: cross-sec- tional survey in an academic menopause center. J Womens Health 2011; 20:559-565.
13. Blake J. Menopause: evidence-based practice. Best Pract Res Clin Obstet Gynaecol 2006;20:799-839.
14. Wren BG. Progesterone creams: do they work? Climacteric 2003;6:184-187.
15. Marchesoni D, Mozzanega B, Maggino T, Nardelli GB. Postmenopausal hot flushes: endocrine correlations and progestinic treatment. Double blind crossed clinical trial using MPA versus placebo. J Gynecol En- docrinol 1985;1:63-69.
16. Schussler P, Kluge M, Yassouridis A, et al. Progesterone reduces wake- fulness in sleep EEG and has no effect on cognition in healthy post- menopausal women. Psychoneuroendocrinology 2008;33:1124-31.
17. Hitchcock CL, Prior JC. Oral micronized progesterone for vasomotor symptoms-a placebo-controlled randomized trial in healthy post- menopausal women. Menopause 2012;19:886-893.
18. Schiff I, Tulchinsky D, Cramer D, Ryan K. Oral medroxyprogesterone in the treatment of postmenopausal symptoms. JAMA 1980;244:1443-1445.
19. Bullock J, Massey F, Gambrell R. Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstet Gynecol 1975;46:165-168.
20. Lobo R, McCormick W, Singer F, Roy S. Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of post- menopausal women. Obstet Gynecol 1984;63:1-5.
21. Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 1999;94:225-228.
22. Benster B, Carey A, Wadsworth F, Vashisht A, Domoney C, Studd J. A double-blind placebo-controlled study to evaluate the effect of pro- gestelle progesterone cream on postmenopausal women. Menopause Int 2009;15:63-69. doi: 10.1258/mi.2009.009014
23. Stephenson K, Neuenschwander PF, Kurdowska AK, Pinson B, Price C. Transdermal progesterone: effects on menopausal symptoms and on thrombotic, anticoagulant, and inflammatory factors in postmenopausal women. Int J Pharm Compd 2008;12:295-304.
24. Wren BG, Champion SM, Willetts K, Manga RZ, Eden JA. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause 2003;10:13-18.
25. Higgins JPT, Green S, eds. The Cochrane Collaboration and John Wiley & Sons, Ltd., West Sussex, England. Cochrane handbook for systematic reviews of interventions, 2011.
26. US Department of Health and Human Services. FDA. Guidance for indus- try: estrogen and estrogen/progestin drug products to treat vasomotor symp- toms and vulvar and vaginal atrophy symptoms-recommendations for clinical evaluation. January 2003. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071643.pdf (accessed 2011 Aug 16).
27. Stanczyk F, Paulson R, Roy S. Percutaneous administration of progesterone: blood levels and endometrial protection. Menopause 2005;12:232-237.
28. Greene JG. Menopause symptoms: climacteric scale. http://www.meno pausematters.co.uk/greenscale.php (accessed 2012 Apr 11).
29. Hilditch JR, Lewis J, Peter A, van Maris B, Ross A, Franssen E. A meno- pause-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996;24:161-175.
30. Fagarasanu M, Kumar S. Measurement instruments and data collection: a consideration of constructs and biases in ergonomics research. Int J Indl Ergon 2002;30:355-369.
31. Major sources of bias in research studies. http://www.umdnj.edu/idsweb/ shared/biases.htm (accessed 2012 Apr 17).
32. Leonetti HB, Wilson KJ, Anasti JN. Topical progesterone cream has an anti-proliferative effect on estrogen-stimulated endometrium. Fertil Steril 2003;79:221-222.